Scotts Miracle-Gro Tops Q2 Sales and EBITDA Estimates
SMG sits 45% above its 52-week low of $45.61.
Summary
Scotts Miracle-Gro reported strong second-quarter results, with sales reaching $1,460 million, surpassing the IBES estimate of $1,405 million. The company also exceeded adjusted EBITDA expectations, posting $437.4 million against an estimate of $399.2 million. This positive performance follows a Q1 fiscal 2026 report that included a significant net loss due to an impairment charge related to its Hawthorne business. Beating both top-line and profitability estimates is a material positive development, indicating robust demand and operational execution in its core segments. Traders will be looking for further details in the full earnings report, particularly updated guidance and commentary on the ongoing divestiture of the Hawthorne division.
At the time of this announcement, SMG was trading at $66.00 on NYSE in the Trade & Services sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $45.61 to $72.35. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.